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Available online 11 February 2016The Genea049 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying a deletion in 4q35 with only 5 D4Z4 repeats by PGD linkage analysis, indicative of FSHD1.
Following ICM outgrowth on inactivated human feeders, karyotype was conﬁrmed as 46, XX by CGH and STR
analysis demonstrated a female Allele pattern. The hESC line had pluripotent cell morphology, 90% of cells
expressed Nanog, 96% Oct4, 80% Tra1–60 and 99% SSEA4, gave a Pluritest Pluripotency score of 23.16, Novelty
of 1.43 and demonstrated Alkaline Phosphatase activity. The cell line was negative for Mycoplasma and visible
contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource TableDame of stem cell line Genea049 — FSHD1 affected (Alternate ID: SIVF049)
stitution Genea BiocellsK
Seerson who created
resourceOmar ChamiPontact person and
emailbiljana.dumevska@geneabiocells.comDate archived/stock
dateAugust, 2009Strigin Human Embryos
pe of resource Derived human embryonic stem cell lineSib-type FSHD1 affected human pluripotent cell line
ey marker
expressionNanog, Oct4, Tra1–60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Figs. 1-2 and Tables 1-2 below)nk to related
literature (direct
URL links and full
references)(Laurent et al., 2011)
http://www.ncbi.nlm.nih.gov/pubmed/?term=21211785formation in public
databasesNational Institutes of Health registered, NIH:
NIHhESC-12-0183
UK Stem Cell Bank registered, UKSCB: SCSC14-54
SNP Data Gene Expression Omnibus accession number,
GEO: GSM638451thical Approval Obtained from the Genea Ethics Committee on 13
September 2005 under the Australian National Health
and Medical Research Council (NHMRC) licence 309,710(B. Dumevska).
. This is an open access article underResource detailstheate of
derivationCC BY-NC-ND licJuly 2009aryotype 46, XX
x Female
luripotent YES — by Alkaline Phosphatase, Nanog, Oct4, Tra1–60, and
SSEA4 staining and Pluritest.
isease status Deletion in 4q35, 5 D4Z4 repeats — Facioscapulohumeral
muscular dystrophy 1 (FSHD1) affected, OMIM: 158900
erility The cell line is tested and found negative for Mycoplasma and
any visible contamination
bling lines
availableYES — GENEA050 (FSHD1 affected — XY, NIH:
NIHhESC-12-0184, UKSCB: SCSC14-54)Materials and methods
Cell line derivation
20% KSR medium (Amit et al., 2000) was conditioned by culture
with high density mitotically inactivated feeders (72,000 cells/cm2)
for 24 h @ 37° 5% CO2 5% O2. The medium is collected and every second
day for a period of 2weeks. Medium from the 2weeks is combined. The
fresh embryo was plated whole onto mitomycin C inactivated human
feeders (Detroit 551 HFF— 90,000/well in 4-well) in feeder conditioned
KSRmediumwith 20 ng/mL FGF added fresh. CGH karyotyping and STR
proﬁling was performed at the ﬁrst cryobanking step from ICM
outgrowths maintained on feeders. Alkaline Phosphatase staining was
performed on feeders. Cells were then enzymatically passaged as single
cells in M2 pluripotent cell maintenance medium (Genea Biocells) and
CGH/karyotyping repeated, immunoﬂuorescent pluripotent markerense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea049 (passage 19) reporting a female cell line and no abnor-
malities detected.
CGH summary
Sample name Genea049p19
Date reported 19th June 2012
Hybridisation balance Balanced hybridization was observed for
chromosomes 1–22, relative to reference DNA
Copy number change No copy number changes N 400 kb were detected
Interpretation Female cell line — no abnormalities detected
Fig. 1. Morphology and karyotype of Genea049. A) Brightﬁeld (passage 1) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 6) on human
inactivated feeders. C) Karyotypic analysis (passage 5, 1 enzymatic) showing 46, XX
normal, female karyotype.
470 B. Dumevska et al. / Stem Cell Research 16 (2016) 469–471staining, pluritest and sterility testing performed following the thawing
of banked vials of frozen stem cells.
Genetic analysis
1. Karyotyping: Passage 5 (4 on feeders, 1 enzymatic); for enrichment
of metaphase cells, cellular outgrowths were incubated with either
0.22 ng/ml colcemid (Invitrogen) and 37.5 g/ml BrdU (Sigma) for
17–19 h or 5 ng/ml colcemid for 2.5 h. Single cells were subsequently
obtained using Non-Enzymatic Cell Dissociation Solution (Sigma)
and transferred to Sydney IVF's (nowGenea) diagnostic cytogenetics
laboratory for preparation of metaphase spreads and cytogenetic
analysis by G-banding. A minimum of 15 metaphase cells were
examined, of which a full karyotype or chromosome counts was
performed for 5 and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 8 (5 on feeders, 3 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and
duplications. CGH was performed using SurePrint G3 microarrays(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).
3. DNA proﬁling: Passage 2; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
Pluripotency assessment
1. Alkaline phosphatase: Passage 6; Genea049 grown on feeders were
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004)
2. Immunoﬂuorescence: Passage 7 (5 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. Pluritest: Passage 8 (5 on feeders, 3 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)
Sterility testing
1. Mycoplasma: Passage 12; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
freemedium (Genea BiocellsM2medium) for 2–3 days at 37 degrees
celsius. A clear solution at ~48–72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation
genetic diagnosis to be affected by known genetic conditions’) was
obtained from the Genea Ethics Committee on 13 September 2005.
Excess ART embryos were fully consented for stem cell derivation
by all responsible people through an informed consent process
(signed de-identiﬁed consent form can be provided upon request).
Donors have received no payment or ﬁnancial beneﬁts for their
donation. Genea049 has been derived from a donated, fully
commercially consented embryo, originally created by assisted re-
production technology (ART) for the purpose of procreation. The
embryo was identiﬁed through pre-implantation genetic diagnosis
to be affected by a genetic mutation and was declared excess to
reproductive needs. Derivation was performed under Australian
Fig. 2. Pluripotency validation of Genea049. A) Immunoﬂuorescent staining (10×) of pluripotent cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 7, 2
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (left) and novelty (right) scores with Genea049 (passage 8, 3 enzymatic) outlined in black.
Table 2
STR proﬁle; Genea049 (passage 2) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF049p2 13 28,30 9 10,11 16,17 6,7 10,11 11 20,23 13,15 17,18 9,11 15,21 11,13 20,23
471B. Dumevska et al. / Stem Cell Research 16 (2016) 469–471ational Health and Medical Research Council (NHMRC) licence
309,710. This licence was issued to GENEA on 7 May 2007. More
information about the licence can be obtained from the NHMRC
webpage at http://www.nhmrc.gov.au/health-ethics/human-
embryos-and-cloning/database-licences-authorising-use-excess-
art-embryosPGD analysis conclusion
Mutation; deletion is 4q35 in the D4Z4 DNA region. Family tree;
Father; b inherited from his Mother. Fragment size observed in patient
(father) was 22.6 kb using p13E-11 DNA probe (Upadhyaya et al.,
1997). Number of D4Z4 repeats calculated from Southern Blot is 5.
Fascio-Scapulo-Humeral-Muscular Dystrophy 1 (FSHD1) affected.Morphology
The derived stem cell line, Genea049, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A/B).Genetic analysis
The cell line has been karyotyped by traditional methods (Fig. 1C,
Supplementary Fig. 1) and CGH (Table 1, Supplementary Fig. 2), which
demonstrated 46, XX karyotype, consistent with original derivation
and pre-implantation genetic diagnosis (PGD). Analysis of STR markers
showed Allele pattern consistent with female genotype (Table 2,
Supplementary Fig. 3).Pluripotency
GENEA049 is pluripotent by;
1. Alkaline phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence with 90% Nanog positive, 96% Oct4 positive,
80% Tra1-60 positive and 99% SSEA4 positive (Fig. 2A, quantiﬁed in
2B).
3. Pluritest with a Pluripotency score of 23.16 and Novelty score of 1.43
(Fig. 2C).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.020.
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